Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health submitted a New Animal Drug Application (NADA) to the FDA for full approval of crofelemer (Canalevia-CA1) to treat chemotherapy-induced diarrhea (CID) in dogs. The submission is supported by a pivotal effectiveness study where 77% of owners reported effectiveness and 40% saw complete resolution of symptoms, compared to 10.5% in untreated cases.
Key figures
- Drug Name
- crofelemer (Canalevia-CA1)
- Phase Of Trial
- pivotal effectiveness study
- Dogs develop cancer stat
- 1 in 4
- Annual dog cancer diagnoses
- 6 million
- Owner reported effectiveness
- 77%
- Cid complete resolution treated
- 40%
- Cid complete resolution untreated
- 10.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.